{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:35:32Z","timestamp":1776195332184,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["Amgen"],"award-info":[{"award-number":["Amgen"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"crossref","award":["Novartis Pharma (AG)"],"award-info":[{"award-number":["Novartis Pharma (AG)"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In patients with migraine, overuse of acute medication, including migraine-specific medication (MSM) such as triptans and ergots, can lead to adverse health outcomes, including development of medication overuse headache. Here, we examined the effect of erenumab on reducing acute medication use, in particular MSM, in patients with episodic migraine (EM) and chronic migraine (CM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The current post-hoc analyses were based on data from the double-blind treatment phase (DBTP) of two erenumab studies, a pivotal EM (<jats:italic>N<\/jats:italic>\u2009=\u2009955) and a pivotal CM (<jats:italic>N<\/jats:italic>\u2009=\u2009667) trial, and their respective extensions. Patients were administered subcutaneous placebo or erenumab (70 or 140\u00a0mg) once monthly. Daily acute headache medication use (including MSM and non-MSM) was recorded using an electronic diary during a 4-week pretreatment baseline period until the end of the treatment period. Outcome measures included change in monthly acute headache medication days (HMD) in acute headache medication users at baseline, and changes in monthly MSM days (MSMD) in MSM users at baseline and non-MSMD in non-MSM users at baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 60 and 78\u2009% of patients (all acute headache medication users) with EM and CM used MSM at baseline, respectively. For acute headache medication users, the change in mean monthly acute HMD over Months 4, 5 and 6 compared with the pre-DBTP was 1.5, 2.5, and 3.0 for placebo, erenumab 70\u00a0mg and 140\u00a0mg, respectively for the EM study. The respective change in monthly MSMD in MSM users was 0.5, 2.1 and 2.8, and in monthly non-MSMD in non-MSM users was 2.3, 2.6, and 2.7. In the acute headache medication users at baseline, the change in monthly acute HMD at Month 3 compared with pre-DBTP was 3.4, 5.5, and 6.5 for placebo, erenumab 70\u00a0mg and 140\u00a0mg, respectively for the CM study. The respective change in monthly MSMD in MSM users was 2.1, 4.5, and 5.4, and in monthly non-MSMD in non-MSM users was 5.9, 6.4, and 6.6. Reductions in MSMD versus placebo were sustained in the extension periods of both studies. Erenumab was also associated with a higher proportion of MSM users achieving\u2009\u2265\u200950\u2009%, \u2265\u200975 and 100\u2009% reduction from baseline in monthly MSMD versus placebo in both EM and CM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In both EM and CM, treatment with erenumab is associated with a significant and sustained reduction in the use of acute headache medication, in particular MSM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registrations<\/jats:title><jats:p>NCT02456740; NCT02066415; NCT02174861.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-021-01292-w","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T11:03:02Z","timestamp":1627038182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Stewart J","family":"Tepper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yngve","family":"Hallstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Broessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo H","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernan","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunfa","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise E","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Klatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D","family":"Mikol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","volume":"47","author":"S Diamond","year":"2007","unstructured":"Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 47:355\u2013363","journal-title":"Headache"},{"key":"1292_CR2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38:1-211","DOI":"10.1177\/0333102417738202"},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-018-0865-z","volume":"19","author":"TJ Schwedt","year":"2018","unstructured":"Schwedt TJ, Alam A, Reed ML et al (2018) Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 19:38","journal-title":"J Headache Pain"},{"key":"1292_CR4","doi-asserted-by":"crossref","unstructured":"Munksgaard SB, Madsen SK, Wienecke T (2019) Treatment of Medication Overuse Headache - a review. Acta Neurol Scand","DOI":"10.1111\/ane.13074"},{"key":"1292_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s40064-016-2211-8","volume":"5","author":"F Antonaci","year":"2016","unstructured":"Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A (2016) Recent advances in migraine therapy. Springerplus 5:637","journal-title":"Springerplus"},{"key":"1292_CR6","doi-asserted-by":"crossref","unstructured":"Porter JK, Di Tanna GL, Lipton RB, Sapra S, Villa G (2018) Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials. Pharmacoecon Open","DOI":"10.1007\/s41669-018-0105-0"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P (2018) Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache 58:700\u2013714","journal-title":"Headache"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.12755","volume":"56","author":"A Messali","year":"2016","unstructured":"Messali A, Sanderson JC, Blumenfeld AM et al (2016) Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. Headache 56:306\u2013322","journal-title":"Headache"},{"key":"1292_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX et al (2016) Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther 356:223\u2013231","journal-title":"J Pharmacol Exp Ther"},{"key":"1292_CR10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/bph.12129","volume":"170","author":"CS Walker","year":"2013","unstructured":"Walker CS, Hay DL (2013) CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? Br J Pharmacol 170:1293\u20131307","journal-title":"Br J Pharmacol"},{"key":"1292_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y et al (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1292_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434","journal-title":"Lancet Neurol"},{"key":"1292_CR13","unstructured":"Tepper S et al (2018) Assessment of the Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Subjects With Chronic Migraine. Data presented at 60th Annual Scientific Meeting of the American Headache Society, San Francisco"},{"key":"1292_CR14","unstructured":"Ashina M et al (2018) Long-term Safety and Tolerability of Erenumab: Three-plus Year Results from an Ongoing Open-Label Extension Study in Episodic Migraine. Data presented at 60th Annual Scientific Meeting of the American Headache Society, San Francisco"},{"key":"1292_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1212\/WNL.0000000000004391","volume":"89","author":"M Ashina","year":"2017","unstructured":"Ashina M, Dodick D, Goadsby PJ et al (2017) Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 89:1237\u20131243","journal-title":"Neurology"},{"key":"1292_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102420973994","volume":"41","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Tepper SJ, Silberstein SD et al (2021) Reversion From Chronic Migraine to Episodic Migraine Following Treatment With Erenumab: Results of a Post Hoc Analysis of a Randomized, 12-Week, Double-Blind Study and a 52-Week, Open-Label Extension. Cephalalgia 41:6\u201316","journal-title":"Cephalalgia"},{"key":"1292_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2018","unstructured":"Goadsby PJ, Paemeleire K, Broessner G et al (2018) Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39:817\u2013826","journal-title":"Cephalalgia"},{"key":"1292_CR18","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Stewart Tepper S, Brandes JL et al (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38:1611\u20131621","journal-title":"Cephalalgia"},{"key":"1292_CR19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL et al (2018) ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38:1026\u20131037","journal-title":"Cephalalgia"},{"key":"1292_CR20","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287","journal-title":"Lancet"},{"key":"1292_CR21","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y et al (2019) A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Headache 59:1731\u20131742","journal-title":"Headache"},{"key":"1292_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382\u2013390","journal-title":"Lancet Neurol"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1468-2982.2008.01660.x","volume":"28","author":"HC Diener","year":"2008","unstructured":"Diener HC, Schorn CF, Bingel U, Dodick DW (2008) The importance of placebo in headache research. Cephalalgia 28:1003\u20131011","journal-title":"Cephalalgia"},{"key":"1292_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11916-009-0048-3","volume":"13","author":"ME Bigal","year":"2009","unstructured":"Bigal ME, Lipton RB (2009) Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep 13:301\u2013307","journal-title":"Curr Pain Headache Rep"},{"key":"1292_CR25","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M et al (2019) Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 92:e2309\u2013e2320","journal-title":"Neurology"},{"key":"1292_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921\u2013936","journal-title":"Headache"},{"key":"1292_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804\u2013814","journal-title":"Cephalalgia"},{"issue":"4","key":"1292_CR28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/head.14068","volume":"61","author":"DM Hines","year":"2021","unstructured":"Hines DM, Shah S, Multani JK et al (2021) Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Headache 61(4):590\u2013602","journal-title":"Headache"},{"issue":"6","key":"1292_CR29","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s12325-021-01677-y","volume":"38","author":"J Fang","year":"2021","unstructured":"Fang J, Korrer S, Johnson JC et al (2021) Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis. Adv Ther 38(6):2921\u20132934","journal-title":"Adv Ther"},{"issue":"1","key":"1292_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-021-01238-2","volume":"22","author":"SJ Tepper","year":"2021","unstructured":"Tepper SJ, Fang J, Vo P et al (2021) Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study. J Headache Pain 22(1):27","journal-title":"J Headache Pain"},{"issue":"1","key":"1292_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32","journal-title":"J Headache Pain"},{"key":"1292_CR32","doi-asserted-by":"crossref","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in Chronic Migraine: An Australian Experience. Headache 60(10):2555\u20132562","DOI":"10.1111\/head.13968"},{"issue":"1","key":"1292_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"3","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D (2020) Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. J Headache Pain 3(1):84","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-021-01292-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-021-01292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T11:17:11Z","timestamp":1699269431000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-021-01292-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1186\/s10194-021-01292-w","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An independent ethics committee at all participating sites for each clinical trial approved the study protocols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SJT was an employee of the Cleveland Clinic during this study. He reports research grants (no personal compensation) from Allergan, Amgen Inc., ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; consultant fees from Acorda, Aeon, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, CRG, Currax, Decision Resources, DeepBench, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Healthcare Consultancy Group, Health Science Communications, Impel, Lundbeck, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pulmatrix, Reckner Healthcare, Relevale, Revance, SAI MedPartners, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, Zosano; advisory boards: Acorda, Aeon, Alder, Allergan, Amgen, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Biohaven, Charleston Laboratories, Currax, Eli Lilly, GSK, Impel, Lundbeck, Novartis, Satsuma, Theranica, Teva, XOC, Zosano; stock options from Nocira, Percept; salary from American Headache Society and Dartmouth-Hitchcock Medical Center; CME honoraria: American Academy of Neurology, American Headache Society, Cleveland Clinic Foundation, Diamond Headache Clinic, Elsevier, Forefront Collaborative, Hamilton General Hospital, Ontario, Canada, Headache Cooperative of New England, Henry Ford Hospital, Detroit, Inova, Medical Learning Institute Peerview, Medical Education Speakers Network, Miller Medical Communications, North American Center for CME, Physicians\u2019 Education Resource, Rockpointe, ScientiaCME, WebMD\/Medscape.MA reports personal fees from Alder, Allergan, Amgen, Eli Lilly, Novartis and Teva, has no ownership interest and does not own stocks of any pharmaceutical company. MA serves as associate editor of Cephalalgia, associate editor of The Journal of Headache and Pain, and associate editor of Headache, and is the current president of the International Headache Society.UR has acted as a consultant for Allergan, Amgen, Eli Lilly, Novartis, Teva, has served on advisory boards for Allergan, Amgen, Autonomic Technologies, Eli Lilly, Medscape, Novartis, Teva, and is a member of speakers\u2019 bureaus for Allergan, Amgen, Eli Lilly, Medscape, Novartis, StreamedUp, Teva, and has received research support from the German Federal Ministry of Education and Research (BMBF) and Novartis. YH has served on advisory boards for Amgen, Novartis and Teva.GB has received unrestricted grants, honoraria, personal fees, and travel grants from Allergan, Amgen, AstraZeneca, European Headache Foundation (EHF), Fresenius, Gr\u00fcnenthal, Janssen Cilag, Lilly, Linde AG, Menarini, Novartis, \u00d6sterreichische Akademie der Wissenschaften (\u00d6AW), \u00d6sterreichische Gesellschaft f\u00fcr Neurologie (\u00d6GN), \u00d6sterreichische Kopfschmerzgesellschaft (\u00d6KSG), Pfizer, Reckitt Benkiser, St. Jude Medical, and Teva.JHB has nothing to disclose.HP is an employee of and stockholder in Amgen.SC is an employee of and stockholder in Amgen.DEC is an employee of and stockholder in Amgen.FZ is an employee of and stockholder in Amgen.JK is an employee of and stockholder in Novartis.DDM is an employee of and stockholder in Amgen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}